계명대학교 의학도서관 Repository

Persistence with solifenacin add-on therapy in men with .benign prostate obstruction and residual symptoms of overactive bladder after tamsulosin monotherapy

Metadata Downloads
Author(s)
Y.-S. LeeK.-S. LeeJ. C. KimS. HongB. H. ChungC.-S. KimJ. G. LeeD. K. KimC. H. ParkJ. K. Park
Keimyung Author(s)
Park, Choal Hee
Department
Dept. of Urology (비뇨의학)
Journal Title
international journal of clinical practice
Issued Date
2014
Volume
68
Issue
12
Abstract
SUMMARY
Aims: In spite of the reported efficacy and safety of antimuscarinics in men with
OAB (overactive bladder) and BPO (benign prostatic obstruction), many patients do
not persist with the treatment. We aimed to evaluate persistence and the reasons
for the discontinuation of solifenacin add-on therapy in men with residual symp-
toms of OAB after tamsulosin monotherapy for BPO in a real clinical environment.
Methods: Men aged ≥ 45 years with IPSS ≥ 12 and symptoms of OAB (OAB-V8
≥ 8, micturition ≥ 8/24 h, urgency ≥ 2/24 h) were prescribed tamsulosin 0.2 mg.
After 4 weeks, men who had residual symptoms of OAB (OAB-V8 ≥ 8, micturition
≥ 8/24 h, urgency ≥ 1/24 h) and reported that they were ‘dissatisfied’ or ‘a little
satisfied’ with the therapy were enrolled and prescribed solifenacin 5 mg in combi-
nation with tamsulosin. After 52 weeks, persistence and the reasons for the dis-
continuation of solifenacin were evaluated. Factors related to persistence were
analysed. Results: Of the 305 men who had been treated with tamsulosin, 176
were prescribed solifenacin. After 52 weeks, 44 (25%) remained on solifenacin
therapy. Of the 132 who discontinued solifenacin, 85 were evaluated on the rea-
son for discontinuation. The three most common reasons for discontinuation were
adverse events (AEs) (35%), lack of efficacy (33%), and improvement in symptoms
(16%). The aggravation of voiding symptoms was the most common AE leading to
discontinuation. Retention was observed in 11 men. None of the demographical or
clinical characteristics were significantly related to persistence. Conclusions: Only
25% men with OAB and BPO remained on antimuscarinic add-on therapy after
1 year, mostly because of AEs and lack of efficacy. Realistic data should be added
to what is already known about antimuscarinic treatment in men by including
patients who were excluded or who dropped out of well-designed clinical trials
Keimyung Author(s)(Kor)
박철희
Publisher
School of Medicine
Citation
Y.-S. Lee et al. (2014). Persistence with solifenacin add-on therapy in men with .benign prostate obstruction and residual symptoms of overactive bladder after tamsulosin monotherapy. international journal of clinical practice, 68(12), 1496–1502. doi: 10.1111/ijcp.12483
Type
Article
ISSN
1368-5031
Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/ijcp.12483
DOI
10.1111/ijcp.12483
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/34475
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Urology (비뇨의학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.